Dravet syndrome, fenfluramine gets reimbursement in Italy

At the press conference announcing the reimbursement of UCB’s new fenfluramine-based drug, indicated in the treatment of seizures associated with Dravet Syndrome in addition to other anti-crisis drugs for patients aged two years or older , Federico Chinni, Chief Executive Officer of UCB Italia, Antonino Romeo, Primary Emeritus of the UOC of Pediatric Neurology and of the Regional Center for Epilepsy of the Fatebenefratelli Hospital in Milan, and Francesca Darra, Head of UOC Child Neuropsychiatry Integrated University Hospital of Verona.